The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

The settlement is the largest deal to date with the people primarily who played an “instrumental role” in driving the opioid ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

The San Diego–based company’s molecules avoid the well-trod GLP-1 pathway in favor of an alternate route in the gut.

Robert F. Kennedy, Jr.’s recent disclosures have revealed several potential conflicts of interest, including investments in ...

Less than a day into his second term, President Donald Trump ordered a freeze on communications at major public health agencies, among other moves that have sent waves through the biopharma industry.

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...

The deal follows a $1.06 billion U.S. contract in July 2024 and a $1.24 billion agreement with an Asia-based pharma a few ...

In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

The U.S. Court of Federal Claims ruled that Vanda cannot claim a breach of confidentiality for specifications that it did not ...